Xeomin

ApprovedSmall molecule

MMerz Therapeutics GmbH

Xeomin is one of 159 small molecule programs targeting Plantar Fasciitis. It is currently in Approved.

Indications

Total Trials

Active Trials

158

Competitors

Pipeline

Status by Indication[3][1]

Indication

Plantar FasciitisActive, not recruiting

Cervical DystoniaActive, not recruiting

Cerebral PalsyActive, not recruiting

StrokeActive, not recruiting

DysmenorrheaActive, not recruiting

BruxismActive, not recruiting

DystoniaApproved

MigraineActive, not recruiting

Plantar FasciitisApproved

Active, not recruiting

Cervical DystoniaApproved

Active, not recruiting

Cerebral PalsyPhase 2

Active, not recruiting

StrokeApproved

Active, not recruiting

DysmenorrheaPhase 3

Active, not recruiting

BruxismPhase 3

Active, not recruiting

DystoniaApproved

Approved

MigrainePreclinical

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

Xeomin

MMerz Therapeutics GmbH

Approved

1 2

Folvite

Eli Lilly

Preclinical

1 3

Savella

AbbVie

Preclinical

1 4

Zometa

Pfizer

Preclinical

1 5

Repatha

Pradaxa

3 7

Botox

RRevance Therapeutics, Inc.

Preclinical

2 8

Alka-Seltzer

AAbbott

Preclinical

1 9

Zantac 150

CChattem

Preclinical

1 10

Direct Anticoagulant

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Post-ApprovalRecruiting

Stroke

NCT04908423

Q4 2027

Phase 3Recruiting

Episodic Migraine

NCT07018700

Phase 3Recruiting

Dystonia

NCT03977493

Q1 2028

Phase 3Recruiting

Chronic Migraine

NCT07018713

Q2 2028

Recruiting

Migraine

NCT07267819

Clinical

Trials by Indication[1]

Glabellar Lines2 trials

To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)

Recruiting·HHuons Biopharma·Phase 3·NCT06205797·312 enrolled

Phase 2 of HU-045 in Glabellar Lines

Completed·HHuons Co., Ltd.·Phase 2·NCT05298449·50 enrolled

Cervical Dystonia2 trials

Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex

Completed·MMerz Pharmaceuticals GmbH·Phase 4·NCT01486264·283 enrolled

Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States

Completed·MMerz North America, Inc.··NCT01287247·688 enrolled

Bruxism1 trial

Evaluation of BTX Injections in Treatment of Bruxism

Unknown status·—·Phase 3·NCT05980559·12 enrolled

Cerebral Palsy1 trial

Treatment With Xeomin Versus Botox in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral Palsy

Completed·MMerz Pharmaceuticals GmbH·Phase 2·NCT02188277·64 enrolled

Dystonia1 trial

IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia

Recruiting·AAlain Kaelin·Phase 3·NCT03977493·48 enrolled

11 more indications

Stroke1 trial

Xeomin® and Gait Related Mobility After Stroke

Recruiting·WWake Forest University Health Sciences·Phase 4·NCT04908423·20 enrolled

Notalgia Paresthetica1 trial

Treatment of Notalgia Paresthetica With Xeomin

Completed·IInnovaderm Research Inc.·Phase 3·NCT01098019·20 enrolled

Completed·IInstituto Portugues da Face·N/A·NCT05027243·46 enrolled

Moderate to Severe Glabellar Frown Lines1 trial

Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines

Unknown status·AATGC Co., Ltd.·Phase 3·NCT05623410·300 enrolled

Plantar Fasciitis1 trial

Treatment of Plantar Fasciitis With Xeomin

Completed·RRothman Institute Orthopaedics·Phase 4·NCT01678001·50 enrolled

PrEP1 trial

Phase IV Study On Muscle Activity Of Two Commercial Preparations Of Botulinum

Completed·HHexsel Dermatology Clinic·Phase 4·NCT01728337·80 enrolled

Primary Dysmenorrhea1 trial

Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection Via Hysteroscopy in Pelvic Pain Suggestive of Dysmenorrhea: A Prospective, Multicenter, Double-Blind, Randomized Placebo-Controlled Study.

Recruiting·NNantes University Hospital·Phase 3·NCT06995287·222 enrolled

Chronic Migraine1 trial

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Trial With Extension Period to Evaluate the Efficacy and Safety of Xeomin® Injections for the Prevention of Chronic Migraine

Recruiting·MMerz Therapeutics GmbH·Phase 3·NCT07018713·780 enrolled

Episodic Migraine1 trial

Recruiting·MMerz Therapeutics GmbH·Phase 3·NCT07018700·990 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Xeomin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Xeomin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Xeomin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merz Therapeutics GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMerz Therapeutics GmbH

Xeomin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q1 2028

Q2 2028

Trials by Indication[1]

Glabellar Lines2 trials

Cervical Dystonia2 trials

Bruxism1 trial

Cerebral Palsy1 trial

Dystonia1 trial

Stroke1 trial

Notalgia Paresthetica1 trial

Botulinum Toxin1 trial

Migraine1 trial

Arthroscopy1 trial

Moderate to Severe Glabellar Frown Lines1 trial

Plantar Fasciitis1 trial

PrEP1 trial

Primary Dysmenorrhea1 trial

Chronic Migraine1 trial

Episodic Migraine1 trial

References

Drug Info

Quick Facts

Related News